Wu et al. identified 24 cases with FGFR1-3 fusions in RNA sequencing data from 322 tumor samples affecting cholangiocarcinoma, breast, prostate, and thyroid cancer, as well as lung squamous cell carcinoma, bladder cancer, head and neck cancer, and glioblastoma [40]. Here, FGFR1 is linked to urinary bladder cancer.